CRA consultants analyzed market power and alleged anticompetitive conduct for a CNS therapy. In defining the relevant antitrust market, our work accounted for indicators of competition among branded pharmaceutical products, including market positioning, factors driving physician choice, development of new approved indications, and competition for formulary listing. Also considered were effects on demand resulting from the change in the form of competition upon the launch of generic products.
CRA adds Harvard Business School Professor as Academic Affiliate to Antitrust & Competition Economics Practice
“I am pleased to welcome Feng to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He is a recognized expert on...